2026 Evidence Brief / Follicle Metabolism
PP405 (PP-405) is an investigational small molecule being studied for its ability to influence the metabolic state of hair-follicle stem cells. Here is what the current clinical program actually shows, why mitochondrial pyruvate transport matters, and what remains unknown.
What is PP405, and how does it work?
PP405 is a topical drug candidate being developed by Pelage Pharmaceuticals. Its proposed approach is to inhibit mitochondrial pyruvate transport, altering the way cells process carbon from glucose. Foundational preclinical work found that reducing mitochondrial pyruvate carrier activity could increase lactate-associated metabolism and activate otherwise resting hair-follicle stem cells in mouse models.
This mechanism differs from the androgen / dihydrotestosterone (DHT) pathway associated with finasteride. PP405 development focuses on a metabolic switch within the follicle, not on 5Ξ±-reductase inhibition. Mechanistic plausibility should not be confused with demonstrated long-term human outcomes.
For compound identity, molecular formula and the JXL069 literature trail, use our detailed PP405 research guide. PP405 is not a peptide despite occasional search results describing it that way.
What did the PP405 Phase 2a study report?
Pelage’s June 17, 2025 company communication described a randomized Phase 2a study enrolling 78 adults with androgenetic alopecia. Participants used the investigational topical formulation or a vehicle comparator for four weeks, with follow-up thereafter. The company reported that its primary safety endpoint was met and that plasma exposure was not detected using the study’s assays.
Among a subgroup of men with more advanced hair loss, Pelage reported that 31% of participants receiving PP405 achieved more than a 20% increase in hair density at week eight, compared with 0% of the corresponding placebo subgroup. These are developer-reported exploratory findings; they are not proof that every patient would benefit or that a retail research solution reproduces the trial result.
When reading such results, distinguish the study’s primary safety endpoint from exploratory efficacy measures, examine subgroup denominators, and wait for larger controlled datasets before drawing firm conclusions about durability and clinical effectiveness.
Latest update: the 2026 AWAKEN Phase 2/3 trial
On October 14, 2026, Pelage announced dosing of the first participant in the AWAKEN Phase 2/3 program, ClinicalTrials.gov identifier NCT07819435. The randomized, blinded, vehicle-controlled study is designed to enroll about 600 men with androgenetic alopecia and assess efficacy and longer-term safety over a 12-month study period.
This is a meaningful development milestone, not FDA approval. PP405 remains an investigational drug. The study formulation, clinical oversight and drug supply are not interchangeable with products sold for laboratory research.
Sources: Pelage’s October 2026 program announcement and the trial registry.
PP405 research FAQs
Is PP405 the same as PP-405?
These spellings refer to the same development code. The molecular identity should nevertheless be checked against a lot-specific analytical record rather than inferred from a marketing name.
Is PP405 FDA approved for hair loss?
No. As of October 29, 2026, the compound remains investigational, with a Phase 2/3 clinical program in progress.
How does PP405 differ from KY19382?
PP405 targets the follicle’s metabolic state via the mitochondrial pyruvate carrier. KY19382 is a preclinical Wnt/Ξ²-catenin pathway compound studied in cells, cultured follicles and mice. Compare the KY19382 research.
Does the clinical result validate a retail PP405 solution?
No. Clinical findings belong to the specific investigational product, study population, protocol and analytical procedures. Check the COA portal for the information reported on each Disguised Alpha lot.
Sources and further reading
- Pelage Pharmaceuticals. Phase 2a results announcement, June 17, 2025 β company-reported findings.
- Pelage Pharmaceuticals. AWAKEN first-patient announcement, October 14, 2026.
- ClinicalTrials.gov. NCT07819435, Phase 2/3 AWAKEN.
- Flores et al. Lactate dehydrogenase activity drives hair follicle stem cell activation. Nature Cell Biology, 2017 β preclinical mechanistic study.
Research and editorial disclosure: Disguised Alpha publishes this educational reference and sells some of the research materials mentioned. Findings from independent investigators or drug developers do not establish the identity, performance, safety or therapeutic efficacy of Disguised Alpha formulations. Research-use-only materials are not intended for human or animal administration, diagnosis, prevention or treatment. This page does not provide dosing advice. Source review: October 29, 2026.